Effectiveness of Intravitreal Chemotherapy-assisted Endoresection in Monocular Patients with Group D Retinoblastoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Aug 28

PMID 32847550

Citations 2

Authors

Xiling Yu

Xueke Li

Yue Xing

Siduo Lu

Silvia Tanumiharjo

Jin Ma

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to determine the efficacy and complications of intravitreal chemotherapy-assisted endoresection for refractory International Classification of Retinoblastoma (ICRB) group D retinoblastoma in monocular patients.

Methods: In this retrospective case series, intravitreal chemotherapy-assisted endoresection by pars plana vitrectomy was performed in 11 eyes with refractory ICRB group D retinoblastoma unresponsive to standard therapies in monocular patients.

Results: Across a mean follow-up period of 42.7 months, globe salvage was attained in all 11 eyes (100%). There were no cases of extra-ocular tumour seeding or remote metastasis. In 9 eyes (81.8%), tumour control was achieved with one pars plana vitrectomy; in 2 cases (18.2%), repeated treatment, such as laser therapy, intravitreal chemotherapy or a second pars plana vitrectomy, was needed. Retinal reattachment was achieved in all 4 eyes (100%) with previous retinal detachment. Four eyes (36.4%) required subsequent cataract surgery due to secondary cataract. Ten eyes (90.9%) had improvement in best-corrected visual acuity at the last follow-up.

Conclusion: Intravitreal chemotherapy-assisted endoresection appears to be a safe and effective globe-salvaging method for refractory group D retinoblastoma. It is a promising alternative to enucleation and a supplementary therapeutic strategy for those unresponsive to standard therapies, especially for the monocular retinoblastoma patients.

Citing Articles

Intraocular Surgery for Retinoblastoma: An Evaluation of Current Evidence.

Gurney S, Abbott J, Millen G, Jenkinson H, Parulekar M Ocul Oncol Pathol. 2024; 10(4):234-246.

PMID: 39660246 PMC: 11627543. DOI: 10.1159/000538626.

Publication Trends of Research on Retinoblastoma During 2001-2021: A 20-Year Bibliometric Analysis.

Gu X, Xie M, Jia R, Ge S Front Med (Lausanne). 2021; 8:675703.

PMID: 34095180 PMC: 8175655. DOI: 10.3389/fmed.2021.675703.

References

Lee J, Han J, Hahn S, Lyu C, Kim D, Lee S . Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds. Graefes Arch Clin Exp Ophthalmol. 2015; 254(2):391-4. DOI: 10.1007/s00417-015-3202-0. View

Shields C, Mashayekhi A, Au A, Czyz C, Leahey A, Meadows A . The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006; 113(12):2276-80. DOI: 10.1016/j.ophtha.2006.06.018. View

Francis J, Brodie S, Marr B, Zabor E, Mondesire-Crump I, Abramson D . Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. Ophthalmology. 2017; 124(4):488-495. PMC: 5441308. DOI: 10.1016/j.ophtha.2016.12.015. View

Honavar S, Shields C, Shields J, Demirci H, Naduvilath T . Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol. 2001; 119(11):1613-21. DOI: 10.1001/archopht.119.11.1613. View

Yarovoy A, Ushakova T, Gorshkov I, Polyakov V, Golubeva O, Gorovtsova O . Intraocular surgery with melphalan irrigation for vitreous hemorrhage in an only eye with retinoblastoma. Eur J Ophthalmol. 2015; 26(1):e17-9. DOI: 10.5301/ejo.5000683. View

Warden S, Mukai S . Pars plana vitrectomy in eyes treated for retinoblastoma. Retina. 2006; 26(7 Suppl):S53-6. DOI: 10.1097/01.iae.0000244289.01875.78. View

Abramson D, Shields C, Munier F, Chantada G . Treatment of Retinoblastoma in 2015: Agreement and Disagreement. JAMA Ophthalmol. 2015; 133(11):1341-7. DOI: 10.1001/jamaophthalmol.2015.3108. View

Shields C, Manjandavida F, Arepalli S, Kaliki S, Lally S, Shields J . Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014; 132(3):319-25. DOI: 10.1001/jamaophthalmol.2013.7666. View

Zhao J, Li Q, Wu S, Jin L, Ma X, Jin M . Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma. Ophthalmology. 2017; 125(2):320-322. DOI: 10.1016/j.ophtha.2017.10.015. View

10.

Ghassemi F, Shields C, Ghadimi H, Khodabandeh A, Roohipoor R . Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014; 132(8):936-41. DOI: 10.1001/jamaophthalmol.2014.414. View

11.

Francis J, Abramson D, Gaillard M, Marr B, Beck-Popovic M, Munier F . The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015; 122(6):1173-9. DOI: 10.1016/j.ophtha.2015.01.017. View

12.

Shields C, Lally S, Leahey A, Jabbour P, Caywood E, Schwendeman R . Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014; 25(5):374-85. DOI: 10.1097/ICU.0000000000000091. View

13.

Munier F . Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014; 35(4):193-207. PMC: 4245997. DOI: 10.3109/13816810.2014.973045. View

14.

Al-Nawaiseh I, Jammal H, Khader Y, Jaradat I, Barham R . Retinoblastoma in Jordan, 2003-2013: ocular survival and associated factors. Ophthalmic Epidemiol. 2014; 21(6):406-11. DOI: 10.3109/09286586.2014.967781. View

15.

Kaneko A, Suzuki S . Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2004; 33(12):601-7. View